-
Je něco špatně v tomto záznamu ?
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
VD. de Jager, W. Timens, A. Bayle, J. Botling, L. Brcic, R. Büttner, MGO. Fernandes, L. Havel, MJ. Hochmair, P. Hofman, A. Janssens, M. Johansson, L. van Kempen, I. Kern, F. Lopez-Rios, M. Lüchtenborg, JC. Machado, K. Mohorcic, L. Paz-Ares, S....
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2021
PubMed Central
od 2021
ROAD: Directory of Open Access Scholarly Resources
od 2020
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness. Moreover, the availability of recently EMA-approved targeted therapies varies between European countries. Unfortunately, routine assessment of national/regional molecular testing rates is limited. As a result, it remains uncertain which proportion of patients with metastatic NSCLC in Europe receive adequate predictive biomarker testing. Lastly, Molecular Tumor Boards (MTBs) for discussion of molecular test results are widely implemented, but national guidelines for their composition and functioning are lacking. The establishment of MTB guidelines can provide a framework for interpreting rare or complex mutations, facilitating appropriate treatment decision-making, and ensuring quality control.
Centre for Cancer Society and Public Health King's College London London United Kingdom
Charles University and Thomayer Hospital Prague Czech Republic
Department of Oncology University Hospital Antwerp University of Antwerp Edegem Belgium
Department of Pathology University Hospital Antwerp University of Antwerp Edegem Belgium
Department of Radiation Sciences Oncology Umeå University Umeå Sweden
Diagnostic and Research Institute of Pathology Medical University of Graz Graz Austria
IHU RespirERA FHU OncoAge Nice University Hospital Côte d'Azur University Nice France
Institute of Medical Genetics and Applied Genomics University of Tuebingen Tuebingen Germany
Institute of Molecular Pathology and Immunology of the University of Porto Porto Portugal
Karl Landsteiner Institute of Lung Research and Pulmonary Oncology Klinik Floridsdorf Vienna Austria
Laboratory for Cytology and Pathology University Clinic Golnik Golnik Slovenia
Lung Unit Royal Marsden NHS Trust London United Kingdom
National Disease Registration Service NHS England London United Kingdom
Oncostat U1018 Inserm Paris Saclay University Gustave Roussy Villejuif France
Pulmonology Department Centro Hospitalar Universitário de São João Porto Portugal
University Clinic of Respiratory and Allergic Diseases Golnik Slovenia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24005671
- 003
- CZ-PrNML
- 005
- 20240412130945.0
- 007
- ta
- 008
- 240405e20240301enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.lanepe.2024.100838 $2 doi
- 035 __
- $a (PubMed)38476742
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a de Jager, Vincent D $u Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 245 10
- $a Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries / $c VD. de Jager, W. Timens, A. Bayle, J. Botling, L. Brcic, R. Büttner, MGO. Fernandes, L. Havel, MJ. Hochmair, P. Hofman, A. Janssens, M. Johansson, L. van Kempen, I. Kern, F. Lopez-Rios, M. Lüchtenborg, JC. Machado, K. Mohorcic, L. Paz-Ares, S. Popat, A. Ryška, P. Taniere, J. Wolf, E. Schuuring, AJ. van der Wekken
- 520 9_
- $a In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness. Moreover, the availability of recently EMA-approved targeted therapies varies between European countries. Unfortunately, routine assessment of national/regional molecular testing rates is limited. As a result, it remains uncertain which proportion of patients with metastatic NSCLC in Europe receive adequate predictive biomarker testing. Lastly, Molecular Tumor Boards (MTBs) for discussion of molecular test results are widely implemented, but national guidelines for their composition and functioning are lacking. The establishment of MTB guidelines can provide a framework for interpreting rare or complex mutations, facilitating appropriate treatment decision-making, and ensuring quality control.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Timens, Wim $u Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 700 1_
- $a Bayle, Arnaud $u Oncostat U1018, Inserm, Paris-Saclay University, Gustave Roussy, Villejuif, France
- 700 1_
- $a Botling, Johan $u Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden
- 700 1_
- $a Brcic, Luka $u Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
- 700 1_
- $a Büttner, Reinhard $u Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany
- 700 1_
- $a Fernandes, Maria Gabriela O $u Pulmonology Department, Centro Hospitalar Universitário de São João, Porto, Portugal
- 700 1_
- $a Havel, Libor $u Charles University and Thomayer Hospital, Prague, Czech Republic
- 700 1_
- $a Hochmair, Maximilian J $u Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria $u Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria
- 700 1_
- $a Hofman, Paul $u IHU RespirERA, FHU OncoAge, Nice University Hospital, Côte d'Azur University, Nice, France
- 700 1_
- $a Janssens, Annelies $u Department of Oncology, University Hospital Antwerp, University of Antwerp, Edegem, Belgium
- 700 1_
- $a Johansson, Mikael $u Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
- 700 1_
- $a van Kempen, Léon $u Department of Pathology, University Hospital Antwerp, University of Antwerp, Edegem, Belgium
- 700 1_
- $a Kern, Izidor $u Laboratory for Cytology and Pathology, University Clinic Golnik, Golnik, Slovenia
- 700 1_
- $a Lopez-Rios, Fernando $u Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre (i+12), Ciberonc, Madrid, Spain
- 700 1_
- $a Lüchtenborg, Margreet $u National Disease Registration Service, NHS England, London, United Kingdom $u Centre for Cancer, Society & Public Health, King's College London, London, United Kingdom
- 700 1_
- $a Machado, José Carlos $u Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal $u Faculty of Medicine of the University of Porto, Institute for Research and Innovation in Health (i3S), Porto, Portugal
- 700 1_
- $a Mohorcic, Katja $u University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia
- 700 1_
- $a Paz-Ares, Luis $u Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, H12O-CNIO Lung Cancer Clinical Research Unit, Research Institute Hospital 12 de Octubre (i+12)/Spanish National Cancer Research Center (CNIO), Ciberonc, Madrid, Spain
- 700 1_
- $a Popat, Sanjay $u Lung Unit, Royal Marsden NHS Trust, London, United Kingdom
- 700 1_
- $a Ryška, Aleš $u The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Czech Republic
- 700 1_
- $a Taniere, Phillipe $u Department of Histopathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
- 700 1_
- $a Wolf, Jürgen $u Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany
- 700 1_
- $a Schuuring, Ed $u Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 700 1_
- $a van der Wekken, Anthonie J $u Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 773 0_
- $w MED00208007 $t The Lancet regional health. Europe $x 2666-7762 $g Roč. 38 (20240301), s. 100838
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38476742 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240405 $b ABA008
- 991 __
- $a 20240412130938 $b ABA008
- 999 __
- $a ok $b bmc $g 2075985 $s 1215433
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 38 $c - $d 100838 $e 20240301 $i 2666-7762 $m The Lancet regional health. Europe $n Lancet Reg Health Eur $x MED00208007
- LZP __
- $a Pubmed-20240405
